Insider Trading Alert - JAZZ, URI And JJSF Traded By Insiders

Yesterday, Feb. 17, 2016, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.30 to $7,252,323.17.

Highlighted Stocks Traded by Insiders:

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Miller Michael Patrick, who is SVP, US Commercial at Jazz Pharmaceuticals, sold 100 shares at $115.63 on Feb. 17, 2016. Following this transaction, the SVP, US Commercial owned 13,461 shares meaning that the stake was reduced by 0.74% with the 100-share transaction.

The shares most recently traded at $123.04, up $7.41, or 6.02% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 8,124
  • 24-Week # shares sold: 48,713

The average volume for Jazz Pharmaceuticals has been 602,900 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.3 billion and is part of the health care sector and drugs industry. Shares are down 12.64% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 22.8. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix